Dyne Therapeutics (DYN) vs Maravai LifeSciences (MRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Dyne Therapeutics (DYN) over the past year, gaining 124.5% versus a gain of 14.5%. Over five years, DYN leads with a +7.3% price change compared with -80.0% for MRVI. Dyne Therapeutics is the larger company by market cap ($2.98 billion vs $2.75 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYN | MRVI |
|---|---|---|
| Share price | $15.97 | $7.43 |
| Market cap | $2.98B | $2.75B |
| 1-day change | +3.70% | -5.35% |
| YTD return | -18.35% | +128.62% |
| 1-year return | +14.48% | +124.47% |
| 5-year return | +7.33% | -79.97% |
| EPS (TTM) | $-3.30 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $185.74M |
| Revenue growth (YoY) | — | -28.34% |
| Net income (latest FY) | $-446.21M | $-130.77M |
| Gross margin | — | 18.30% |
| Operating margin | — | -115.89% |
| Net margin | — | -70.41% |
| 52-week high | $27.31 | $9.42 |
| 52-week low | $13.73 | $2.55 |
| Distance from 52-week high | -41.51% | -21.13% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +125.42% | +5.38% |
| Average volume | 2.78M | 3.33M |
| Shares outstanding | 186.75M | 148.99M |
| Employees | 289 | 415 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed DYN by 110.0 percentage points over the past year.
About Dyne Therapeutics
DYN stock →Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 289 employees
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
DYN vs MRVI FAQ
Which is bigger, Dyne Therapeutics or Maravai LifeSciences?
Dyne Therapeutics (DYN) is larger, with a market capitalization of $2.98B compared with $2.75B for Maravai LifeSciences (MRVI).
Which stock has performed better over the past year, DYN or MRVI?
MRVI returned +124.47% over the past 12 months, compared with +14.48% for DYN (price return, excluding dividends). Past performance does not predict future results.
Are Dyne Therapeutics and Maravai LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.